Novartis AG
New York Stock Exchange•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Vasant Narasimhan
- Full Time Employees
- 75,883
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- Lichtstrasse 35 Basel Switzerland 4056
- IPO Date
- Nov 7, 1996
- CIK
- 0001114448
- Website
- novartis.com
- Similar Companies
- Business
- Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Company News
Why Novartis (NVS) is a Top Value Stock for the Long-Term
Novartis gets approval for first malaria drug for babies and children
Novartis receives approval for first malaria medicine for newborn babies and young infants
Here's Why Novartis (NVS) is a Strong Momentum Stock
Novartis' Cosentyx Misses Primary Goal in Arteritis Phase III Study
Novartis drug Cosentyx fails late-stage trial for artery disease
Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)
Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)
Buy These 5 Low-Leverage Stocks Amid Wall Street's Tricky July Start
Novartis AG (NVS) Hits Fresh High: Is There Still Room to Run?
7 Killer European Stocks To Buy In July
Final Trades: Novartis, Sixth Street, Amazon and the IYF
ProFound Therapeutics Announces Multi-Year Strategic Collaboration with Novartis to Discover and Develop Novel Therapeutics for Cardiovascular Disease
Novartis completes acquisition of Regulus Therapeutics
Novartis: A SWAN Worth Owning
5 Large Drug Stocks That Are Poised to Ride on Sector Recovery
Buy These 5 Low-Leverage Stocks Amid Fresh Iran-Israel War
Novartis AG (NVS) Hit a 52 Week High, Can the Run Continue?
Novartis' Fabhalta Delivers Hemoglobin Gains, Reduces Fatigue In Patients With Rare Blood Disorder
Novartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH